title: Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.
abstract: OBJECTIVE
  Expression of various members of the ErbB family (epidermal growth factor receptor/ErbB-1, ErbB-2, ErbB-3 and ErbB-4) is associated with disease stage and survival in patients with urothelial carcinoma. We examined the correlation of ErbB family receptor expression with the progression of urothelial carcinoma and survival.
  
  
  METHODS
  A urothelial carcinoma tissue array was constructed from 248 archival paraffin blocks and quality control studies were ascertained. The tissue microarray was stained for epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4, and analyzed using an automated reader. Patient data included grade, stage, growth pattern, recurrence and survival.
  
  
  RESULTS
  Kaplan-Meier estimates of 5-year overall and recurrence-free survival were 58% and 27%, respectively. Patients with high grade, invasive or nonpapillary disease had a worse prognosis than patients with low grade, superficial or papillary disease (p <0.0001). High epidermal growth factor receptor or low ErbB-4 expression was associated with nonpapillary, high grade and invasive tumors as well as with significantly shorter recurrence-free and overall survival (p <0.002, 0.028 and 0.047, respectively). Levels of ErbB-2 and ErbB-3 expression were not associated with overall or recurrence-free survival.
  
  
  CONCLUSIONS
  The expression profiles of ErbB-4 and epidermal growth factor receptor are prognostic in urothelial carcinoma. They may help in selecting patients at high risk with bladder cancer for more aggressive therapy.
authors.affiliation: Division of Urology, McGill University Health Center, Montreal, Quebec, Canada.
authors.forename: Wassim
authors.initials: W
authors.lastname: Kassouf
authors.forename: Peter C
authors.initials: PC
authors.lastname: Black
authors.forename: Tomasz
authors.initials: T
authors.lastname: Tuziak
authors.forename: Jolanta
authors.initials: J
authors.lastname: Bondaruk
authors.forename: Sangkyou
authors.initials: S
authors.lastname: Lee
authors.forename: Gordon A
authors.initials: GA
authors.lastname: Brown
authors.forename: Liana
authors.initials: L
authors.lastname: Adam
authors.forename: Caimiao
authors.initials: C
authors.lastname: Wei
authors.forename: Keith
authors.initials: K
authors.lastname: Baggerly
authors.forename: Menashe
authors.initials: M
authors.lastname: Bar-Eli
authors.forename: David
authors.initials: D
authors.lastname: McConkey
authors.forename: Bogdan
authors.initials: B
authors.lastname: Czerniak
authors.forename: Colin P
authors.initials: CP
authors.lastname: Dinney
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D018450:Disease Progression; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D020893:Receptor, ErbB-3 / Q000096:biosynthesis*; D066247:Receptor, ErbB-4; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology
chemical_list: D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; C587689:ERBB4 protein, human